European Council Funds Alzheimer’s Mini-Protein Project
The Mini-Me project aims to develop treatments for protein-misfolding diseases using a novel AI-driven approach.
Updated on Oct. 15, 2026 in Alzheimer’s
Live Poll
Should the government prioritize funding long-term medical research projects to find future disease treatments?
The European Innovation Council has awarded a research grant to the Mini-Me project, an initiative focused on treating protein misfolding diseases. This international consortium, which includes ResQ Biotech and the University of Cambridge, works to identify mini-proteins capable of inhibiting aggregation and clearing fibrils from brain tissue.
Why it matters
The project aims to establish a scalable platform for discovering drug candidates for more than 100 conditions caused by protein misfolding. Its development builds upon the success of the drug candidate RSQ-020, which has demonstrated an ability to restore memory in pre-clinical animal trials.
The Mini-Me consortium comprises eight partners across six European countries and is eligible for grants of up to 4 million euros. The project is one of 43 initiatives chosen from a total of 2,103 proposals submitted for funding.
The players
European Innovation Council
This body is a European Commission agency responsible for identifying and funding high-risk, high-impact innovations across the continent.
ResQ Biotech
This biotechnology firm specializes in developing innovative protein-based therapies for neurodegenerative disorders.
University of Cambridge
This public collegiate research university is a world-leading institution known for its contributions to medical and scientific advancements.
The details
The research team utilizes artificial intelligence to optimize cyclical mini-proteins designed to break down toxic aggregates. This approach specifically targets the root causes of neurodegenerative disease by clearing protein fibrils found in patient brain tissue.
Timeline
October 15, 2026: The funding selection is reported.
The Big Picture
This award is part of the EIC Pathfinder Open program, which supports early-stage research into breakthrough technologies with high commercialization potential. It follows the program's mandate to support high-risk, high-reward research projects that require collaborative international development.
While currently in pre-clinical stages, this research offers a future pathway toward potential new drug therapies for neurodegenerative diseases. Patients and families may eventually see new treatment options targeting the underlying mechanisms of protein misfolding.
The takeaway
The use of AI-driven protein engineering marks a significant technical pivot in the search for neurodegenerative treatments. Research progress in this field continues to move toward identifying molecules that can address the root causes of cellular protein aggregation.
Further reading
Learn more about ongoing research into Alzheimer’s.
Source note: This article includes information reported by The National Herald.
Live Poll
Should the government prioritize funding long-term medical research projects to find future disease treatments?
